Cytek Biosciences (CTKB) Stock Forecast: StockMap's 2-Week Call

CTKB stock forecast: StockMap's model leans Outperform on Cytek Biosciences for the two weeks after the Nov 19 close, toward CTKB doing better than the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 5 two-week windows on CTKB since Aug 21; by chance, a call on the same dates was right 67% of the time.

Cytek Biosciences last closed at $6.32, +6.76% on the session.

Against the IVW growth benchmark the position is +9.09% over the forecast window.

Cytek Biosciences' market cap is $826.58M as of November 19, 2026.

Leans up ↗: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 27 (too close to call).

Where CTKB sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 33%.

34 daily calls for CTKB so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Cytek Biosciences in the 25th percentile on return on equity, where 100 is best.

Cytek Biosciences is classified under Health Care / Life Sciences Tools & Services.

StockMap tracks Cytek Biosciences as the 31st largest of the 42 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 23 Neutral, 16 Moderate Outperform and 3 Moderate Underperform.

On that composite Cytek Biosciences ranks 10th of 42 in the group, against a group median of +0.13.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Cytek Biosciences (CTKB) — StockMap 2-week forecast & tracked accuracy